肝动脉栓塞化疗联合氩氦刀冷冻消融治疗不能手术的中晚期肝癌的临床观察

目的观察肝动脉栓塞化疗联合氩氦刀冷冻消融治疗不能手术的中晚期肝癌的有效性和安全性。方法对35例原发性肝癌患者首先进行动脉栓塞化疗治疗，2～3周后进行氩氦刀冷冻消融治疗，氩氦刀冷冻消融治疗后1～2周再次进行动脉栓塞化疗，治疗结束后评价近期疗效，并随访生存情况。结果35例患者均可评价疗效，其中完全缓解7例，部分缓解21例，稳定4例，进展3例，临床有效率为80．00％（28／35），疾病控制率为91．43％（32／35）。患者中位无进展生存（PFS）为8．9个月，中位总生存（OS）为16．3个月。结论肝动脉栓塞化疗联合氩氦刀冷冻消融治疗不能手术的原发性肝癌创伤小、恢复快、并发症少、疗效可靠。

Clinical observation of transcatheter arterial chemoembolization combined with argon-helium cryoablation on 35 patients with advanced unresectable primary hepatocellular carcinoma

Objective To evaluate the efficacy and safety of transcatheter arterial ehemoembolization combined with argon-helium cryoablation on patients with advanced unresectable primary hepatocellular carcinoma. Methods Transcatheter arterial chemoembolization was performed in 35 patients with primary hepatocellular carcinoma,then argon-helium cryoablation was done after 2-3 weeks.The second transcatheter arterial chemoembolization treatment was performed 1-2 week after argon-helimn cryoablation. The after treatment response was evaluated and the toxicity was observed. Rnsnlts Thirty-five patients were evaluated. Complete response was observed in 7 patients, partial response in 21 patients, stable disease in 4 patients and progressive disease in 3 patients. Overall response rate was 80.00 %（28/35）, and disease control rate was 91.43 %（32/35）. Patients＇ median PFS was 8.9 months, median OS was 16.3 months. Conclusion The therapeutic effect of transcatheter arterial ehemoembolization combined with argon-helium cryoablation is good in treating advanced unresectable primary hepatocellular carcinoma.